Abstract
Two PDE4D gene polymorphisms [SNP41 (rs152312 and SNP87 (rs2910829)] were studied in patients with acute stroke (n = 577) and in control sample (n = 270). Significant differences in the genotype and allele frequency distribution were found between these samples for polymorphism SNP41. We showed that the AA and AG genotypes of SNP41 polymorphism were associated with higher risk of acute stroke development in the Moscow population (OR = 1.6). No association of SNP87 polymorphism with the disease was observed.
This is a preview of subscription content, log in via an institution to check access.
References
Gretarsdottir, S., Sveinbjörnsdottir, S., Jonsson, H.H., et al., Localization of a Susceptibility Gene for Common Forms of Stroke to 5q12, Am. J. Hum. Genet., 2002, vol. 70, no. 3, pp. 593–603.
Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S.T., et al., The Gene Encoding Phosphodiesterase 4D Confers Risk of Ischemic Stroke, Nat. Genet., 2003, vol. 35, no. 2, pp. 131–138.
Fukumoto, S., Koyama, H., Hosoi, M., et al., Distinct Role of cAMP and cGMP in the Cell Cycle Control of Vascular Smooth Muscle Cells: cGMP Delays Cell Cycle Transition through Suppression of Cyclin D1 and Cyclin-Dependent Kinase 4 Activation, Circ. Res., 1999, vol. 85, no. 11, pp. 985–991.
Houslay, M.D. and Adams, D.R., PDE4 cAMP Phosphodiesterases: Modular Enzymes That Orchestrate Signalling Cross-Talk, Desensitization and Compartmentalization, Biochem. J., 2003, vol. 370, pp. 1–18.
Pan, X., Arauz, E., Krzanowski, J.J., et al., Synergistic Interactions between Selective Pharmacological Inhibitors of Phosphodiesterase Isozyme Families PDE III and PDE IV to Attenuate Proliferation of Rat Vascular Smooth Muscle Cells, Biochem. Pharmacol., 1994, vol. 48, no. 4, pp. 827–835.
Palmer, D., Tsoi, K., and Maurice, D.H., Synergistic Inhibition of Vascular Smooth Muscle Cell Migration by Phosphodiesterase 3 and Phosphodiesterase 4 Inhibitors, Circ. Res., 1998, vol. 82, no. 8, pp. 852–861.
Indolfi, C., Avvedimento, E.V., Di Lorenzo, E., et al., Activation of cAMP-PKA Signaling in vivo Inhibits Smooth Muscle Cell Proliferation Induced by Vascular Injury, Nat. Med., 1997, vol. 3, no. 7, pp. 775–779.
Indolfi, C., Di Lorenzo, E., Rapacciuolo, A., et al., 8-Chloro-cAMP Inhibits Smooth Muscle Cell Proliferation in vitro and Neointima Formation Induced by Balloon Injury in vivo, J. Am. Coll. Cardiol., 2000, vol. 36, no. 1, pp. 288–293.
Lusis, A.J., Atherosclerosis, Nature, 2000, vol. 407, no. 6801, pp. 233–241.
Libby, P., Inflammation in Atherosclerosis, Nature, 2002, vol. 420, no. 6917, pp. 868–874.
Naghavi, M., Libby, P., Falk, E., et al., From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies. Part I, Circulation, 2003, vol. 108, no. 14, pp. 1664–1672.
Munshi, A. and Kaul, S., Stroke Genetics-Focus on PDE4D Gene, Int. J. Stroke, 2008, vol. 3, no. 3, pp. 188–192.
Liu, H. and Maurice, D.H., Phosphorylation-Meditated Activation and Translocation of the Cyclic AMP-Specific Phosphodiesterase PDE4D3 by Cyclic AMP-Dependent Protein Kinase and Mitogen-Activated Protein Kinases: A Potential Mechanism Allowing for the Coordinated Regulation of PDE4D Activity and Targeting, J. Biol. Chem., 1999, vol. 274, no. 15, pp. 10557–10565.
Szpirer, C., Szpirer, J., Rivière, M., et al., Chromosomal Localization of the Human and Rat Genes (PDE4D and PDE4B) Encoding the cAMP-Specific Phosphodiesterases 3 and 4, Cytogenet. Cell Genet., 1995, vol. 69, nos. 1–2, pp. 11–14.
Bevan, S. and Markus, H., The Genetics of Stroke, ACNR, 2004, vol. 4, no. 4, pp. 9–11.
Gulcher, J.R., Gretarsdottir, S., Helgadottir, A., et al., Genes Contributing to Risk for Common Forms of Stroke, Trends Mol. Med., 2005, vol. 11, no. 5, pp. 217–224.
Bersano, A., Ballabio, E., Bresolin, N., et al., Genetic Polymorphisms for the Study of Multifactorial Stroke, Hum. Mutat., 2008, vol. 29, no. 6, pp. 776–795.
Hsieh, M-S., Yu, S-C., Chung, W-T., et al., Phosphodiesterase 4D (PDE4D) Gene Variants and Risk of Ischemic Stroke in the Taiwanese Population, Lab. Med., 2009, vol. 40, no. 2, pp. 87–90.
Jacob, C., Martin-Chouly, C., and Lagente, V., Type 4 Phosphodiesterase Dependent Pathways: Role in Inflammatory Processes, Therapie, 2002, vol. 57, no. 2, pp. 163–168.
Hakonarson, H., Role of FLAP and PDE4D in Myocardial Infarction and Stroke: Target Discovery and Future Treatment Options, Curr. Treat. Options Cardiovasc. Med., 2006, vol. 8, no. 3, pp. 183–192.
Giovannoni, M.P., Cesari, N., Graziano, A., et al., Synthesis of Pyrrolo[2,3-d]pyridazinones as Potent, Subtype Selective PDE4 Inhibitors, J. Enzyme Inhib. Med. Chem., 2007, vol. 22, no. 3, pp. 309–318.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © E.A. Bondarenko, T.V. Tupitsina, P.A. Slominsky, I.M. Shetova, N.A. Shamalov, A.Yu. Botsina, V.I. Skvortsova, S.A. Limborska, 2010, published in Genetika, 2010, Vol. 46, No. 6, pp. 861–864.
Rights and permissions
About this article
Cite this article
Bondarenko, E.A., Tupitsina, T.V., Slominsky, P.A. et al. Phosphodiesterase 4D (PDE4D) gene polymorphism in patients with acute stroke from Moscow. Russ J Genet 46, 765–768 (2010). https://doi.org/10.1134/S1022795410060189
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1022795410060189